Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Bernd Schnabl

    TitleAssociate Professor In Residence
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0063
    CA La Jolla 92093
    Phone858-822-5311
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      The Role of the Intestinal Mycobiome in Alcoholic Liver Disease
      NIH/NIAAA U01AA024726Apr 10, 2017 - Mar 31, 2022
      Role: Principal Investigator
      The Commensal Microflora Suppresses Liver Fibrosis
      VA I01BX002213Oct 1, 2014 - Sep 30, 2018
      Role: Principal Investigator
      Microbiome as Therapeutic Target in Alcoholic Hepatitis
      NIH/NIAAA U01AA021856Jun 1, 2013 - May 31, 2018
      Role: Principal Investigator
      Microbiome and intestinal innate immune response in alcoholic liver disease
      NIH/NIAAA R01AA020703Sep 25, 2011 - Jun 30, 2021
      Role: Principal Investigator
      Blocking toll-like receptor 4 signaling as therapy in hepatic fibrosis
      NIH/NIDDK K08DK081830Sep 30, 2009 - Jun 30, 2014
      Role: Principal Investigator

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Hochrath K, Schnabl B. Check your microbiota when taking the drug. Hepatology. 2017 Aug 06. PMID: 28782199.
        View in: PubMed
      2. Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017 Jun 30; 127(7):2829-2841. PMID: 28530644.
        View in: PubMed
      3. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017 May 02; 25(5):1054-1062.e5. PMID: 28467925.
        View in: PubMed
      4. Brandl K, Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017 May; 33(3):128-133. PMID: 28257306.
        View in: PubMed
      5. Stärkel P, Schnabl B. Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease. Semin Liver Dis. 2016 Sep; 36(4):331-339. PMID: 27997973.
        View in: PubMed
      6. Eguchi A, Lazaro RG, Wang J, Kim J, Povero D, Willliams B, Ho SB, Stärkel P, Schnabl B, Ohno-Machado L, Tsukamoto H, Feldstein AE. Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. Hepatology. 2017 Feb; 65(2):475-490. PMID: 27639178.
        View in: PubMed
      7. Inamine T, Yang AM, Wang L, Lee KC, Llorente C, Schnabl B. Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. Alcohol Clin Exp Res. 2016 Dec; 40(12):2604-2613. PMID: 27739086.
        View in: PubMed
      8. Patel NS, Hooker J, Gonzalez M, Bhatt A, Nguyen P, Ramirez K, Richards L, Rizo E, Hernandez C, Kisseleva T, Schnabl B, Brenner D, Sirlin CB, Loomba R. Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017 Mar; 15(3):463-464. PMID: 27712981.
        View in: PubMed
      9. Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016 Dec 01; 311(6):G1018-G1036. PMID: 27686615.
        View in: PubMed
      10. Llorente C, Schnabl B. Fast-Track Clearance of Bacteria from the Liver. Cell Host Microbe. 2016 07 13; 20(1):1-2. PMID: 27414492.
        View in: PubMed
      11. Chen P, Miyamoto Y, Mazagova M, Lee KC, Eckmann L, Schnabl B. Microbiota and Alcoholic Liver Disease. Alcohol Clin Exp Res. 2016 Aug; 40(8):1791-2. PMID: 27364225.
        View in: PubMed
      12. Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, Fernández J, To U, García-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers. 2016 06 09; 2:16041. PMID: 27277335.
        View in: PubMed
      13. Fuchs M, Schnabl B. Editors' Introduction to the NAFLD and NASH Special Issue. Dig Dis Sci. 2016 May; 61(5):1211-3. PMID: 27068170.
        View in: PubMed
      14. Schnabl B. Liver capsule: Mechanisms of alcoholic hepatitis. Hepatology. 2016 Jul; 64(1):276. PMID: 26867027.
        View in: PubMed
      15. Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe. 2016 Feb 10; 19(2):227-39. PMID: 26867181; PMCID: PMC4786170 [Available on 02/10/17].
      16. Nakamoto N, Schnabl B. Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West? Inflamm Intest Dis. 2016 Apr; 1(1):3-8. PMID: 27243019.
        View in: PubMed
      17. Ho SB, Matheny ME, Schnabl B. Changes in Hospital Admissions and Mortality for Complications of Cirrhosis: Implications for Clinicians and Health Systems. Gut Liver. 2016 Jan; 10(1):8-9. PMID: 26696026; PMCID: PMC4694728.
      18. Hartmann P, Seebauer CT, Mazagova M, Horvath A, Wang L, Llorente C, Varki NM, Brandl K, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. Am J Physiol Gastrointest Liver Physiol. 2016 Mar 01; 310(5):G310-22. PMID: 26702135; PMCID: PMC4773827 [Available on 03/01/17].
      19. Schnabl B, Farshchi-Heydari S, Loomba R, Mattrey RF, Hoh CK, Sirlin CB, Brenner DA, Behling CA, Vera DR. Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. Nucl Med Biol. 2016 Feb; 43(2):179-87. PMID: 26872443.
        View in: PubMed
      20. Chen P, Miyamoto Y, Mazagova M, Lee KC, Eckmann L, Schnabl B. Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury. Alcohol Clin Exp Res. 2015 Dec; 39(12):2313-23. PMID: 26556636; PMCID: PMC4712135 [Available on 12/01/16].
      21. Brenner DA, Paik YH, Schnabl B. Role of Gut Microbiota in Liver Disease. J Clin Gastroenterol. 2015 Nov-Dec; 49 Suppl 1:S25-7. PMID: 26447960; PMCID: PMC4602394 [Available on 11/01/16].
      22. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015 Nov; 63(5):1272-84. PMID: 26192220.
        View in: PubMed
      23. Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert Rev Gastroenterol Hepatol. 2015; 9(8):1069-76. PMID: 26088524; PMCID: PMC4828034.
      24. Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 2015 May; 39(5):763-75. PMID: 25872593; PMCID: PMC4402724.
      25. Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015 May 01; 1(3):275-284. PMID: 26090511.
        View in: PubMed
      26. Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015 Aug; 13(8):1513-20.e1. PMID: 25661453.
        View in: PubMed
      27. Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology. 2015 Mar; 61(3):883-94. PMID: 25251280; PMCID: PMC4340725.
      28. Wang L, Llorente C, Hartmann P, Yang AM, Chen P, Schnabl B. Methods to determine intestinal permeability and bacterial translocation during liver disease. J Immunol Methods. 2015 Jun; 421:44-53. PMID: 25595554; PMCID: PMC4451427.
      29. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky JM, Saltiel AR, Downes M, Evans RM. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015 Feb; 21(2):159-65. PMID: 25559344; PMCID: PMC4320010.
      30. Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, Eckmann L, Dhungana S, Pathmasiri W, Sumner S, Westwater C, Brenner DA, Schnabl B. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 2015 Mar; 29(3):1043-55. PMID: 25466902; PMCID: PMC4422368.
      31. Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015 Jan; 148(1):203-214.e16. PMID: 25239591; PMCID: PMC4274236.
      32. Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, Loomba R. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):561-568.e1. PMID: 25218667; PMCID: PMC4333065.
      33. Schnabl B. The Microbiome and the Liver. Gastroenterol Hepatol (N Y). 2014 Aug; 10(8):519-521. PMID: 28845144.
        View in: PubMed
      34. Chen P, Schnabl B. Host-microbiome interactions in alcoholic liver disease. Gut Liver. 2014 May; 8(3):237-41. PMID: 24827618; PMCID: PMC4026639.
      35. Schnabl B. Transplanting a fibrogenic microbiota. Hepatology. 2014 May; 59(5):1660-1. PMID: 24676698.
        View in: PubMed
      36. Wang L, Hartmann P, Haimerl M, Bathena SP, Sjöwall C, Almer S, Alnouti Y, Hofmann AF, Schnabl B. Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. J Hepatol. 2014 Jun; 60(6):1259-67. PMID: 24560660; PMCID: PMC4028388.
      37. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Ginès P. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014 Jun; 60(6):1310-24. PMID: 24530646.
        View in: PubMed
      38. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014 May; 146(6):1513-24. PMID: 24440671; PMCID: PMC3996054.
      39. Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterol Res Pract. 2013; 2013:498296. PMID: 24348536; PMCID: PMC3855930.
      40. Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology. 2013 Jul; 58(1):108-19. PMID: 23408358; PMCID: PMC3695050.
      41. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013 May; 29(3):264-70. PMID: 23493073; PMCID: PMC4077188.
      42. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012 Nov 08; 491(7423):254-8. PMID: 23034650; PMCID: PMC3601659.
      43. Hartmann P, Chen WC, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol. 2012; 3:402. PMID: 23087650; PMCID: PMC3468817.
      44. Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012 Nov; 143(5):1330-40.e1. PMID: 22841787; PMCID: PMC3482543.
      45. Brandl K, Tomisato W, Li X, Neppl C, Pirie E, Falk W, Xia Y, Moresco EM, Baccala R, Theofilopoulos AN, Schnabl B, Beutler B. Yip1 domain family, member 6 (Yipf6) mutation induces spontaneous intestinal inflammation in mice. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):12650-5. PMID: 22802641; PMCID: PMC3412000.
      46. Schnabl B, Brenner DA. Fibroblast growth factor inducible 14 as potential target in patients with alcoholic hepatitis. Gut. 2013 Mar; 62(3):335-6. PMID: 22717452; PMCID: PMC4077319.
      47. Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S, Schnabl B, Seki E, De Minicis S, Oesterreicher C, Taura K. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair. 2012; 5(Suppl 1):S17. PMID: 23259769; PMCID: PMC3368775.
      48. Yan AW, Schnabl B. Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol. 2012 Apr 27; 4(4):110-8. PMID: 22567183; PMCID: PMC3345535.
      49. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, Brenner DA, Schnabl B. Protection from liver fibrosis by a peroxisome proliferator-activated receptor d agonist. Proc Natl Acad Sci U S A. 2012 May 22; 109(21):E1369-76. PMID: 22538808; PMCID: PMC3361396.
      50. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012 Jun; 56(6):1283-92. PMID: 22326468; PMCID: PMC3357486.
      51. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012 Feb 01; 590(3):447-58. PMID: 22124143; PMCID: PMC3379693.
      52. Schnabl B, Czech B, Valletta D, Weiss TS, Kirovski G, Hellerbrand C. Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease. Int J Clin Exp Pathol. 2011; 4(7):661-6. PMID: 22076166; PMCID: PMC3209606.
      53. Schnabl B, Valletta D, Kirovski G, Hellerbrand C. Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. Exp Mol Pathol. 2011 Dec; 91(3):695-701. PMID: 21840307; PMCID: PMC3342774.
      54. Brenner DA, Seki E, Taura K, Kisseleva T, Deminicis S, Iwaisako K, Inokuchi S, Schnabl B, Oesterreicher CH, Paik YH, Miura K, Kodama Y. Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res. 2011 Jul; 41(7):683-6. PMID: 21711427; PMCID: PMC3341613.
      55. Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, Osterreicher CH, Kisseleva T, Brenner DA. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology. 2011 May; 53(5):1730-41. PMID: 21384410; PMCID: PMC3082608.
      56. Siggs OM, Schnabl B, Webb B, Beutler B. X-linked cholestasis in mouse due to mutations of the P4-ATPase ATP11C. Proc Natl Acad Sci U S A. 2011 May 10; 108(19):7890-5. PMID: 21518881; PMCID: PMC3093471.
      57. Tacke F, Zimmermann HW, Trautwein C, Schnabl B. CXCL5 plasma levels decrease in patients with chronic liver disease. J Gastroenterol Hepatol. 2011 Mar; 26(3):523-9. PMID: 21332547; PMCID: PMC3058722.
      58. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011 Jan; 53(1):96-105. PMID: 21254165; PMCID: PMC3059122.
      59. Schnabl B, Bettenay S, Glos N, Linek M, Loewenstein C, Mueller RS. Oral selamectin in the treatment of canine generalised demodicosis. Vet Rec. 2010 Jun 05; 166(23):710-4. PMID: 20525946.
        View in: PubMed
      60. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010 Jul; 139(1):323-34.e7. PMID: 20347818; PMCID: PMC4631262.
      61. Kodama Y, Kisseleva T, Iwaisako K, Miura K, Taura K, De Minicis S, Osterreicher CH, Schnabl B, Seki E, Brenner DA. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology. 2009 Oct; 137(4):1467-1477.e5. PMID: 19549522; PMCID: PMC2757473.
      62. Brandl K, Rutschmann S, Li X, Du X, Xiao N, Schnabl B, Brenner DA, Beutler B. Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response. Proc Natl Acad Sci U S A. 2009 Mar 03; 106(9):3300-5. PMID: 19202076; PMCID: PMC2651297.
      63. Kodama Y, Taura K, Miura K, Schnabl B, Osawa Y, Brenner DA. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. Gastroenterology. 2009 Apr; 136(4):1423-34. PMID: 19249395.
        View in: PubMed
      64. De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF, Brenner DA. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology. 2008 Dec; 48(6):2016-26. PMID: 19025999.
        View in: PubMed
      65. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008 Nov; 48(5):1420-9. PMID: 18671304.
        View in: PubMed
      66. Gäbele E, Mühlbauer M, Dorn C, Weiss TS, Froh M, Schnabl B, Wiest R, Schölmerich J, Obermeier F, Hellerbrand C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun. 2008 Nov 14; 376(2):271-6. PMID: 18760996.
        View in: PubMed
      67. Brandl K, Plitas G, Mihu CN, Ubeda C, Jia T, Fleisher M, Schnabl B, DeMatteo RP, Pamer EG. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature. 2008 Oct 09; 455(7214):804-7. PMID: 18724361; PMCID: PMC2663337.
      68. Schnabl B, Brandl K, Fink M, Gross P, Taura K, Gäbele E, Hellerbrand C, Falk W. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun. 2008 Oct 17; 375(2):210-4. PMID: 18694726.
        View in: PubMed
      69. Schnabl B, Scholten D, Brenner DA. What is the potential role of antifibrotic agents for the treatment of liver disease? Nat Clin Pract Gastroenterol Hepatol. 2008 Sep; 5(9):496-7. PMID: 18628735.
        View in: PubMed
      70. Tacke F, Trautwein C, Yagmur E, Hellerbrand C, Wiest R, Brenner DA, Schnabl B. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol. 2007 Aug; 22(8):1256-64. PMID: 17688666.
        View in: PubMed
      71. Brandl K, Plitas G, Schnabl B, DeMatteo RP, Pamer EG. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med. 2007 Aug 06; 204(8):1891-900. PMID: 17635956; PMCID: PMC2118673.
      72. Tacke F, Gäbele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, Straub RH, Luedde T, Manns MP, Trautwein C, Brenner DA, Schölmerich J, Schnabl B. Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci. 2007 Dec; 52(12):3404-15. PMID: 17415633.
        View in: PubMed
      73. Schnabl B, Bettenay SV, Dow K, Mueller RS. Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. Vet Rec. 2006 Jan 21; 158(3):81-5. PMID: 16428661.
        View in: PubMed
      74. Meiler C, Muhlbauer M, Johann M, Hartmann A, Schnabl B, Wodarz N, Schmitz G, Scholmerich J, Hellerbrand C. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J Gastroenterol. 2005 Oct 14; 11(38):6031-7. PMID: 16273620; PMCID: PMC4436730.
      75. Wiest R, Jurzik L, Moleda L, Froh M, Schnabl B, von Hörsten S, Schölmerich J, Straub RH. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. J Hepatol. 2006 Mar; 44(3):512-9. PMID: 16324766.
        View in: PubMed
      76. Schnabl B, Hu K, Mühlbauer M, Hellerbrand C, Stefanovic B, Brenner DA, Schölmerich J. Zinc finger protein 267 is up-regulated during the activation process of human hepatic stellate cells and functions as a negative transcriptional regulator of MMP-10. Biochem Biophys Res Commun. 2005 Sep 16; 335(1):87-96. PMID: 16054593.
        View in: PubMed
      77. Hu K, Fink M, Froh M, Gäbele E, Hellerbrand C, Mühlbauer M, Wiest R, Schölmerich J, Schnabl B. Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor Y. Biochim Biophys Acta. 2005 May 25; 1729(1):14-23. PMID: 15814297.
        View in: PubMed
      78. Schnabl B, Choi YH, Hagedorn CH, Bataller R. DNA microarrays and data mining to study hepatic fibrosis. Methods Mol Med. 2005; 117:359-69. PMID: 16118462.
        View in: PubMed
      79. Mühlbauer M, Weiss TS, Thasler WE, Gelbmann CM, Schnabl B, Schölmerich J, Hellerbrand C. LPS-mediated NFkappaB activation varies between activated human hepatic stellate cells from different donors. Biochem Biophys Res Commun. 2004 Dec 03; 325(1):191-7. PMID: 15522218.
        View in: PubMed
      80. Stefanovic B, Stefanovic L, Schnabl B, Bataller R, Brenner DA. TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and is necessary for collagen type I synthesis. Mol Cell Biol. 2004 Feb; 24(4):1758-68. PMID: 14749390; PMCID: PMC344171.
      81. Kweon YO, Paik YH, Schnabl B, Qian T, Lemasters JJ, Brenner DA. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol. 2003 Jul; 39(1):38-46. PMID: 12821042.
        View in: PubMed
      82. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology. 2003 Mar; 37(3):653-64. PMID: 12601363.
        View in: PubMed
      83. Stefanovic B, Schnabl B, Brenner DA. Inhibition of collagen alpha 1(I) expression by the 5' stem-loop as a molecular decoy. J Biol Chem. 2002 May 17; 277(20):18229-37. PMID: 11889120.
        View in: PubMed
      84. Schnabl B, Choi YH, Olsen JC, Hagedorn CH, Brenner DA. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest. 2002 Mar; 82(3):323-33. PMID: 11896211.
        View in: PubMed
      85. Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA. TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology. 2001 Nov; 34(5):953-63. PMID: 11679966.
        View in: PubMed
      86. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 2001 Jul; 34(1):89-100. PMID: 11431738.
        View in: PubMed
      87. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol. 2001 Jun 01; 166(11):6812-9. PMID: 11359840.
        View in: PubMed
      Bernd's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _